Immunocore (NASDAQ:IMCR) CAO John Goll Sells 698 Shares of Stock

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) CAO John Goll sold 698 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $22,580.30. Following the transaction, the chief accounting officer directly owned 653 shares of the company’s stock, valued at approximately $21,124.55. The trade was a 51.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Immunocore Price Performance

NASDAQ:IMCR traded down $0.67 during trading hours on Friday, reaching $32.50. The stock had a trading volume of 127,005 shares, compared to its average volume of 455,268. The stock has a market capitalization of $1.64 billion, a PE ratio of -57.02 and a beta of 0.78. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $23.15 and a 52 week high of $40.71. The company has a 50 day moving average price of $33.89 and a two-hundred day moving average price of $34.30. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00.

Wall Street Analyst Weigh In

A number of equities analysts have commented on IMCR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, January 22nd. Zacks Research upgraded Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Mizuho set a $38.00 price objective on Immunocore in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Immunocore presently has a consensus rating of “Moderate Buy” and an average target price of $60.90.

Trending Headlines about Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst coverage and institutional ownership point to upside: several brokers maintain positive outlooks (examples cited include UBS and Wells Fargo) and the consensus average price target remains well above the current price (~$60.90 average target reported), while institutional ownership is high (~84.5%), which can support share stability and long-term demand. MarketBeat IMCR Coverage
• Neutral Sentiment: Strong liquidity on the balance sheet: Immunocore shows very healthy current and quick ratios (~6.00 and ~5.97), which reduces short-term solvency risk but is unlikely to drive near-term share moves by itself. Trading volume today was well below average, which can amplify price moves on news. (No definitive short-interest signal — reported short-interest data appears inconsistent/buggy and should be treated cautiously.)
• Negative Sentiment: Significant insider selling: CEO Bahija Jallal sold 11,474 shares at an average of $32.35 (≈$371k), reducing her stake by ~48%. Multiple other insiders (including David M. Berman, CAO John Goll and Tina Leger) also sold large portions of their holdings on the same day. Such clustered insider dispositions can be read negatively by the market and put downward pressure on the stock. InsiderTrades: CEO Sells IMCR SEC Form 4 (Berman)

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Leonteq Securities AG purchased a new position in Immunocore during the 4th quarter valued at $30,000. GAMMA Investing LLC boosted its stake in shares of Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after purchasing an additional 311 shares during the period. Harbour Investments Inc. grew its holdings in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after purchasing an additional 388 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Immunocore by 4,696.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after buying an additional 1,268 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new stake in Immunocore during the 2nd quarter valued at about $42,000. Institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.